Cargando…

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tun, Aung M., Wang, Yucai, Matin, Aasiya, Inwards, David J., Habermann, Thomas M., Micallef, Ivana, Johnston, Patrick B., Porrata, Luis, Paludo, Jonas, Bisneto, Jose Villasboas, Rosenthal, Allison, Tun, Han W., Cerhan, James R., Witzig, Thomas E., Nowakowski, Grzegorz S., Ansell, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079336/ https://www.ncbi.nlm.nih.gov/pubmed/37034004 http://dx.doi.org/10.1097/HS9.0000000000000869

Ejemplares similares

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Long‐term outcome of immunologic autograft engineering
por: Porrata, Luis F., et al.
Publicado: (2022)

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
por: Porrata, Luis F., et al.
Publicado: (2010)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure
por: Gile, Jennifer J., et al.
Publicado: (2021)

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
por: Villasboas, Jose Caetano, et al.
Publicado: (2016)

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
por: Porrata, Luis F., et al.
Publicado: (2013)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
por: Chohan, Karan L., et al.
Publicado: (2022)

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
por: Porrata, Luis F., et al.
Publicado: (2015)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
por: Chohan, Karan L., et al.
Publicado: (2022)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
por: Bock, Allison M., et al.
Publicado: (2023)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
por: Breen, William G., et al.
Publicado: (2023)

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
por: Tracy, S I, et al.
Publicado: (2017)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
por: Bezerra, Evandro D., et al.
Publicado: (2022)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
por: Powell, Marissa Z., et al.
Publicado: (2023)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
por: Bock, A., et al.
Publicado: (2022)

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
por: Witzig, T E, et al.
Publicado: (2011)

The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells
por: Abeykoon, Jithma P., et al.
Publicado: (2019)

History of autoimmune conditions and lymphoma prognosis
por: Kleinstern, Geffen, et al.
Publicado: (2018)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hwang, Steven, et al.
Publicado: (2023)

Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
por: King, Rebecca L., et al.
Publicado: (2022)

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
por: Breen, William G., et al.
Publicado: (2022)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_sqv3ttkqlc6r6od39l0mlf9qq7